🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesGLP-1 and beta-cell preservation — need advice Page 2

GLP-1 and beta-cell preservation — need advice

KevinCompounds Thu, Jul 3, 2025 at 3:27 AM 19 replies 1,499 viewsPage 2 of 4
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
Jul 4, 2025 at 3:18 AM#6
KevinCompounds said:
HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very…

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 36% to 19%. Target is <36%, with <30% being ideal.

Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.

Last edited: Jul 4, 2025 at 9:18 AM
23 18MikeFit_NJ, InsuranceTom, WendyG_ATL and 20 others
Reply Quote Save Share Report
TinaHashiRN
Member
345
1,567
Sep 2024
Raleigh, NC
Jul 4, 2025 at 12:48 PM#7

One thing that is still open after PharmD_Rodriguez’s answer:

How long did you give it before you decided it was working?

22 17mike_mod, SarahChen_PharmD, sarah.morrison and 19 others
Reply Quote Save Share Report
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Jul 4, 2025 at 10:19 PM#8
Dr.PathRoch said:
Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 36% to 19%.

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)1311019585
Insulin (fasting)2715115
HOMA-IR5.53.72.31.5
Uric Acid8.47.16.25.2

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 5.5 to near 1.0 is a metabolic transformation.

21 16maya_sedona, stefan_berlin, Dr.EM_Chicago and 18 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
KevinCompounds
VIP Member
5,432
18,234
Dec 2023
Nevada
Jul 5, 2025 at 7:50 AM#9
Dr.PathRoch said:
Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 36% to 19%.

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 4.5 (insulin resistant) → Current = 1.3 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

20 15BenResearch_OR, MikeKY_noInsulin, Dr.RaviCardio and 17 others
Reply Quote Save Share Report
nick_newbie
New Member
18
56
Jun 2026
Virginia
Online
Jul 7, 2025 at 5:31 AM#10
TrialTracker_MD said:
Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone: Test Baseline Month 3 Month 6 Month 12…

Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction than glucose or A1C.

My fasting insulin: 31 → 15 → 7 uIU/mL over 9 months. Target is <7. By the time your fasting glucose is elevated, your insulin has been elevated for YEARS trying to compensate.

Ask your doctor to include fasting insulin in your bloodwork panel. It's cheap (~$20) and incredibly informative.

Last edited: Jul 7, 2025 at 8:31 AM
4 2wanda_boise, NurseAsh_DET, BenResearch_OR and 1 other
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register